Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Xencor, inc. symbols : GLAXF save search
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
Published: 2022-03-25 (Crawled : 21:00) - biospace.com/
GLAXF | $20.2 510
|
Health Technology
|
| O: 4.57%
H: 0.0%
C: -3.26%
GSK | $39.44 -0.4% 560K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
XNCR | $19.0 -0.37% 120K
|
Health Technology
|
| O: -0.7%
H: 1.94%
C: -1.47%
VIR | $8.18 -0.85% 270K
|
Health Technology
|
| O: -1.07%
H: 0.8%
C: -12.62%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
drug food authorization emergency use authorization
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GSK | $39.44 -0.4% 560K
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
XNCR | $19.0 -0.37% 120K
|
Health Technology
|
| O: 0.38%
H: 1.12%
C: -1.31%
VIR | $8.18 -0.85% 270K
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published: 2021-12-17 (Crawled : 13:30) - globenewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 2.36%
H: 0.46%
C: 0.46%
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: 0.0%
GSK | $39.44 -0.4% 560K
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
XNCR | $19.0 -0.37% 120K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
VIR | $8.18 -0.85% 270K
|
Health Technology
|
| O: -4.59%
H: 0.0%
C: 0.0%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
covid-19 treatment europe granted covid authorization grant
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
Published: 2021-12-07 (Crawled : 09:00) - globenewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: 3.63%
H: 0.0%
C: 0.0%
GSK | $39.44 -0.4% 560K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
XNCR | $19.0 -0.37% 120K
|
Health Technology
|
| O: -2.12%
H: 4.74%
C: 2.8%
VIR | $8.18 -0.85% 270K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
preclinical sars-cov-2 pre-clinical
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
INVO | $1.36 78.95% 3.6M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.